Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Uterine Tumor With Myogenic Differentiation and SRF::RELA Fusion Manifesting as Endometrial Polyp.

Created on 06 Aug 2026

Authors

Monika Manethová, Jan Hojný, Pavel Dundr

Published in

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. Aug 05, 2026. Epub Aug 05, 2026.

Abstract

We report a case of a uterine mesenchymal tumor with myogenic differentiation and SRF::RELA fusion occurring in a 23-year-old woman manifesting as an endometrial polyp. The tumor consisted of bland spindle cells with a predominantly fascicular growth pattern and entrapment of the endometrial glands and vessels. The tumor was positive for smooth muscle markers and CD10. NGS RNA analysis revealed SRF::RELA fusion. NGS DNA analysis revealed no pathogenic variants or copy-number alterations. On follow-up 12 months after curettage, the patient showed no signs of the disease. To the best of our knowledge, only 3 cases of uterine tumors with SRF::RELA fusion arising in the gynecologic tract have been described previously, and all show benign behavior so far. Differential diagnosis includes both benign and potentially aggressive entities, such as leiomyoma, inflammatory myofibroblastic tumor, perivascular epithelioid cell tumor, uterine adenosarcoma, low-grade endometrial stromal sarcoma, and uterine sarcoma with KAT6B/A::KANSL1 fusion.

PMID:
42555852
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement